[Golimumab (Simponi)--first subcutaneous anti-TNF with once-monthly application].
نویسندگان
چکیده
Reumatizam 2010. 57(2) 1Klinika za reumatske bolesti i rehabilitaciju Referentni centar MZSS RH za reumatoidni artritis Klinički bolnički centar Zagreb Kišpatićeva 12 10000 Zagreb 2Zavod za kliničku imunologiju i reumatologiju Klinika za unutarnje bolesti Klinički bolnički centar Zagreb Kišpatićeva 12 10000 Zagreb 3Odjel za reumatologiju i kliničku imunologiju Klinika za internu medicinu Klinički bolnički centar Rijeka Krešimirova 42 51000 Rijeka SPONZORIRANO PRIOPĆENJE SPONSORED COMMUNICATION
منابع مشابه
Golimumab for the treatment of ulcerative colitis
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or becom...
متن کاملGolimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis" (2010). Rheumatology Publications and Presentations. Paper 114. Introduction: The introduction of tumor necrosis factor-α (TNF-α) inhibitors represented a significant advance in the management of rheumatoid arthritis (RA) and other chronic inflam-matory di...
متن کاملGolimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
INTRODUCTION The introduction of tumor necrosis factor-alpha (TNF-alpha) inhibitors represented a significant advance in the management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. Although three TNF-alpha inhibitors have been approved for the treatment of RA by the US Food and Drug Administration (FDA) and the European Medicinal Products Evaluation Agency (EMEA), not a...
متن کاملAchieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab.
Anti–tumor necrosis factor (TNF) agents have become established in the induction and maintenance of response and remission for patients with ulcerative colitis (UC). Golimumab (Simponi, Janssen) is a subcutaneously administered anti-TNF agent that gained US Food and Drug Administration approval in May 2013 for the treatment of moderate-to-severe UC that is refractory to prior treatment or requi...
متن کاملGolimumab: A Novel Anti-Tumor Necrosis Factor
• Golimumab is the first human monoclonal antibody to tumor necrosis factor (TNF) administered monthly by subcutaneous injection (pre-filled syringe or pre-filled pen, auto-injector). • The drug is approved by the U.S. Food and Drug Administration and by the European Medicines Agency for the treatment of severe/moderate active forms of Rheumatoid arthritis, psoriatic arthritis, and ankylosing s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Reumatizam
دوره 57 2 شماره
صفحات -
تاریخ انتشار 2010